Biotech-Start-up G.ST Antivirals starts first clinical trial

New therapeutic approach against rhinovirus infections

Less than three years after its foundation, the start-up G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital. G.ST Antivirals is testing a nasal spray, which was developed specifically for use against colds and other upper respiratory tract infections.

Based on years of research into metabolic changes in infected cells, the new nasal spray is designed to inhibit rhinoviruses in their reproduction by preventing glucose utilisation and consequently starving them. This stops the spread of the virus and successfully combats it. The initial focus is on classical colds – additionally, the therapeutic approach is promising for prevention and treatment of various respiratory diseases, including Covid-19. The clinical phase I started on March 31st at the Department of Clinical Pharmacology at the Vienna General Hospital: the first of 45 probands was enrolled. The aim of phase I is to investigate the safety of the substance. The following phase II, which is expected to take place in 2023, will examine the effectiveness of the substance for infected people. The market launch is scheduled to take place in three to four years.

“The pandemic has shown that the treatment of viral infections is an incredibly important field of research. But the importance goes far beyond Covid-19: Rhinoviruses, which are the focus of our studies, are among the most common pathogens in various respiratory diseases. These include the classical cold, but also aggravations of conditions like asthma and cystic fibrosis in childhood and in COPD patients,” says Dr. Guido Gualdoni, G.ST Antivirals Co-Founder and Managing Director. “Although millions of people get a cold every year, no drug has yet been able to stop the virus from multiplying. Our innovative therapeutic approach deprives viruses of the basis for their reproduction. The results so far make us confident that we will be able to provide an effective drug soon.”

First curative drug against rhinoviruses

For more than nine years, the physicians and founders Dr. Guido Gualdoni and Prof. Johannes Stöckl studied the mechanism underlying the therapy at the Medical University of Vienna. The core finding: Cells infected with viruses switch to an anabolic metabolic state and react particularly sensitive to an inhibition of sugar utilisation at this stage. Based on this discovery, the research duo developed a highly effective, patented therapy against rhinoviruses. The pathogens, which cause colds and rhinitis among other things, use the metabolism of the infected cell for their reproduction. To this end, they depend on a constant supply of sugar. This is precisely where the new therapeutic approach of G.ST Antivirals comes in: The nasal spray contains a glucose analogue that inhibits the utilisation of sugar by rhinovirus and therefore significantly prevents it from reproducing.

“Many areas of research are still unexplored in the field of respiratory diseases – we want to close this gap with our approach. Unlike many other concepts, our technology does not focus on the virus itself, but on the treatment of the host cell. This perspective ensures particularly diverse application possibilities and the development of resistance is highly unlikely,” explains Gualdoni.

About G.ST Antivirals

G.ST Antivirals is an Austrian start-up founded in 2019 as a spin-off from the Medical University of Vienna. The young company has its roots in extensive research on the inhibition of rhinovirus infections. Based on this, G.ST Antivirals developed a patented, innovative drug against colds. Since its foundation, the start-up has specialized in the development of effective therapies against various viral infections using its own developed approach. After a successful funding round in 2020, start of clinical phase 1 at the Department of Clinical Pharmacology followed in 2022. The start-up currently employs eight people in Vienna and Guido Gualdoni is the company’s CEO. For their invention, the two founders Guido Gualdoni and Johannes Stöckl received the award “Inventor of the Year” by the Medical University of Vienna in 2020.

Rückfragen & Kontakt:

Guido Gualdoni, MD, PhD
Chief Executive Officer
G.ST Antivirals GmbH
Dr. Bohr-Gasse 7
A-1030 Vienna
Tel: +43 664 1869460

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)